Karyopharm Therapeutics Inc. (KPTI) Receives Average Rating of “Buy” from Brokerages
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus rating of “Buy” from the eleven research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.25.
Several research analysts have recently commented on KPTI shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 price target (up from $16.00) on shares of Karyopharm Therapeutics in a report on Thursday, August 10th. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 8th.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/karyopharm-therapeutics-inc-kpti-receives-average-rating-of-buy-from-brokerages-2/1581094.html.
Shares of Karyopharm Therapeutics (KPTI) traded up 1.43% during midday trading on Friday, hitting $10.63. 164,275 shares of the stock traded hands. The stock’s market cap is $501.08 million. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63. The firm has a 50-day moving average price of $9.40 and a 200 day moving average price of $9.83.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period last year, the firm posted ($0.84) earnings per share. Karyopharm Therapeutics’s revenue for the quarter was down 95.0% on a year-over-year basis. Analysts anticipate that Karyopharm Therapeutics will post ($2.67) earnings per share for the current year.
In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 8,000 shares of company stock valued at $85,024 over the last three months. 14.71% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of KPTI. Vanguard Group Inc. boosted its stake in Karyopharm Therapeutics by 31.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after purchasing an additional 384,658 shares during the period. Teachers Advisors LLC lifted its stake in shares of Karyopharm Therapeutics by 915.0% in the 1st quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after acquiring an additional 379,127 shares during the period. Iguana Healthcare Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the 1st quarter worth approximately $3,531,000. EAM Investors LLC acquired a new stake in shares of Karyopharm Therapeutics in the 1st quarter worth approximately $3,462,000. Finally, Candriam Luxembourg S.C.A. lifted its stake in shares of Karyopharm Therapeutics by 154.7% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after acquiring an additional 266,000 shares during the period. 58.97% of the stock is owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.